Publication details

Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial

Authors	SEKERES Mikkael A MONTESINOS Pau NOVAK Jan WANG Jianxiang JEYAKUMAR Deepa TOMLINSON Benjamin MAYER Jiří JOU Erin ROBAK Tadeusz TAUSSIG David C DOMBRET Herve MERCHANT Akil SHAIK Naveed BRIEN Thomas ROH Whijae LIU Xueli MA Wendy DIRIENZO Christine G CHAN Geoffrey CORTES Jorge E
Year of publication	2023
Type	Article in Periodical
Magazine / Source	Leukemia
MU Faculty or unit	Faculty of Medicine
Citation
Web	https://www.nature.com/articles/s41375-023-02008-6
Doi	http://dx.doi.org/10.1038/s41375-023-02001-z
Keywords	polycythemia vera; ropeginterferon alfa-2b
Description	This is the primary report of the randomized, placebo-controlled phase 3 BRIGHT AML 1019 clinical trial of glasdegib in combination with intensive chemotherapy (cytarabine and daunorubicin) or non-intensive chemotherapy (azacitidine) in patients with untreated acute myeloid leukemia. Overall survival (primary endpoint) was similar between the glasdegib and placebo arms in the intensive (n = 404; hazard ratio [HR] 1.05; 95% confidence interval [CI]: 0.782-1.408; two-sided p = 0.749) and non-intensive (n = 325; HR 0.99; 95% CI: 0.768-1.289; two-sided p = 0.969) studies. The proportion of patients who experienced treatment-emergent adverse events was similar for glasdegib versus placebo (intensive: 99.0% vs. 98.5%; non-intensive: 99.4% vs. 98.8%). The most common treatment-emergent adverse events were nausea, febrile neutropenia, and anemia in the intensive study and anemia, constipation, and nausea in the non-intensive study. The addition of glasdegib to either cytarabine and daunorubicin or azacitidine did not significantly improve overall survival and the primary efficacy endpoint for the BRIGHT AML 1019 phase 3 trial was not met. Clinical trial registration: ClinicalTrials.gov: NCT03416179.